Market Insights
Stay Up-to-Date With the Latest News in the Targeted Protein Degradation Field.
Browse Our Exclusive Content Below
NEW INTERVIEW
Nurix Interview
5th Targeted Protein Degradation Summit
Hear from Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix Therapeutics, as he shares his thoughts on the TPD field and why he’s excited about the upcoming conference. He also gives a sneak peek to what he and the Nurix team will be presenting next month.
<< Check out the full interview here
Asha Therapeutics Interview
5th Targeted Protein Degradation Summit
As part of our interview series for the flagship 5th Annual TPD Summit, I caught up with Sam Shrivastava, Founder & CEO of Asha Therapeutics whose research centers around their novel PRISMTM platform. Check out the full interview here.
Beacon Brainstorms Podcast:
Alessio Ciulli on Drug Design and the Future of TPD
Sofia Rodriguez talks to Alessio Ciulli, professor of chemical structural biology at the University of Dundee and Co-Founder of Amphista Therapeutics, the leading Europe-based TPD company. Join us to hear about his lab's ground-breaking research into protein degradation, the opening of the new Centre for Targeted Protein Degradation (CeTPD), and the opportunities and challenges of novel degrader design.
